Valneva (VLA) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
16 Nov, 2026Business profile and strategy
Develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs; proprietary travel vaccines include IXIARO, DUKORAL and IXCHIQ.
Strategy: grow commercial vaccines to generate cash for R&D, deliver clinical milestones, expand a balanced pipeline and strengthen integrated manufacturing and commercial operations.
Three proprietary vaccines have advanced from research through multiple approvals; integrated operations support vaccine expertise and development execution.
Commercial portfolio and pipeline
IXIARO is approved for Japanese encephalitis from 2 months of age; DUKORAL is approved for cholera and, in some markets, ETEC from 2 years of age.
IXCHIQ is authorized for chikungunya in healthy adults in Europe and Canada from age 12, and in Brazil from age 18; the U.S. BLA was suspended in August 2025 and voluntarily withdrawn in January 2026.
Pipeline includes LB6V/VLA15 for Lyme disease, VLA1553 for chikungunya, S4V2 for shigellosis, VLA2112 for EBV and an ETEC vaccine candidate.
Lyme disease vaccine opportunity
Lyme disease market estimate exceeds $1bn globally; 87m people in the U.S. and 223m in Europe live in high-risk areas, while annual reported cases are ~476k and >132k, respectively.
LB6V/VLA15 targets six prevalent Borrelia serotypes covering >97% of cases in the U.S. and Europe; Pfizer partnership includes tiered sales royalties of 14%-22% and potential upfront and milestone payments up to $408m, of which $165m has been received.
Phase 3 pre-specified season 2 analysis showed vaccine efficacy of 73% (95% CI 16, 94) from day 28 after dose 4 and 75% (95% CI 22, 94) from day 1; the first analysis missed its pre-determined statistical criterion, while the second had a lower CI bound >20.
Candidate was well tolerated with no safety concerns identified at analysis; EMA validated the marketing authorization application, with regulatory decisions expected within 12 months.
Pfizer expects decisions within 12 months; up to $143m in early commercialization milestones may be payable, alongside the potential for broad use in high-risk populations age 5+.
Latest events from Valneva
- Lyme regulatory progress and a fall 2027 Europe launch remain the central catalysts.VLA
Jefferies Global Healthcare Conference - Sales grew as IXCHIQ launched and the Lyme vaccine advanced through Phase 3.VLA
Q4 2023 - Revenue and product sales fell, but cash position improved and 2026 guidance reaffirmed.VLA
Q2 2026 - Late-stage Lyme vaccine, strong pipeline, and €135–€150m 2026 sales guide strategic growth.VLA
Company presentation - 2025 revenues hit €174.7m, proprietary sales rose 9%, and key vaccine milestones are ahead.VLA
Q4 2025 - Revenue up 8.9% to €127M; net loss widens, but financial flexibility and guidance reaffirmed.VLA
Q3 2025 - Revenue up 37.8% to €97.6M; strong vaccine sales, reduced cash burn, and key milestones achieved.VLA
Q2 2025 - Net profit of €24.7M, strong vaccine sales, and pipeline progress support positive outlook.VLA
Q3 2024 - Q1 2025 revenue up 50% with strong vaccine sales, margin gains, and pipeline progress.VLA
Q1 2025